Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow margin | (13.3%) | (53.3%) | 31.9% | 7.1% | (52.0%) | (44.7%) | (0.7%) | (44.6%) | (9.0%) | 20.5% | 14.9% | 15.9% | 20.0% | 17.6% | 27.0% | 25.4% | 23.6% | 40.6% | 36.3% | 28.0% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 24.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for Regeneron Pharmaceuticals, Inc. have been 33.2% over the past three years, and 32.2% over the past five years.
As of today, Regeneron Pharmaceuticals, Inc.'s Free Cash Flow margin is 24.4%, which is higher than industry median of (753.4%). It indicates that Regeneron Pharmaceuticals, Inc.'s Free Cash Flow margin is Good.